Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database
Stéphane Dalle(Mount Sinai Hospital), Brigitte Dréno(Inserm), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Célèste Lebbé(Inserm), S. Dalac‐Rat(Centre Hospitalier du Mans), A. Dupuy(Hôpital Pontchaillou), Jean‐Michel Nguyen(Inserm), Henri Montaudié(Hôpital l'Archet), Émilie Varey(Inserm), F. Skowron, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Nicolás Meyer(Université Toulouse III - Paul Sabatier), C. Lesage(Université de Montpellier), Amir Khammari(Inserm), Laurent Mortier, P. Celérier(Roche (France))
Cited by 3
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k